Stocktoria
ZIMMER BIOMET HOLDINGS, INC. ZBH
NYSE · stock · Orthopedic, Prosthetic & Surgical Appliances & Supplies · website · IPO 2001-07-25 · LEI
ZIMMER BIOMET HOLDINGS, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.2B | $7.7B | $7.4B | $6.9B | $6.8B | $6.1B | $8.0B | $7.9B | $7.8B | $7.7B |
| SG&A expense | $3.3B | $2.9B | $2.8B | $2.8B | $2.8B | $2.7B | $3.3B | $3.4B | $3.1B | $2.9B |
| Operating income | $1.1B | $1.3B | $1.3B | $696.3M | $860.3M | $83.1M | $1.1B | $33.8M | $799.3M | $821.1M |
| Income tax | $125.7M | $131.4M | $42.2M | $112.3M | $53.5M | -$96.0M | -$225.7M | $108.2M | -$1.3B | $95.0M |
| Net income | $705.1M | $903.8M | $1.0B | $231.4M | $401.6M | -$138.9M | $1.1B | -$379.2M | $1.8B | $305.9M |
| EPS (diluted) | $3.55 | $4.43 | $4.88 | $1.10 | $1.91 | $-0.67 | $5.47 | $-1.86 | $8.90 | $1.51 |
| Operating cash flow | $1.7B | $1.5B | $1.6B | $1.4B | $1.5B | $1.2B | $1.6B | $1.7B | $1.6B | $1.6B |
| Free cash flow | $1.5B | $1.3B | $1.3B | $1.2B | $1.4B | $1.1B | $1.4B | $1.6B | $1.4B | $1.4B |
| Cash & equivalents | $591.9M | $525.5M | $415.8M | $375.7M | $378.1M | $802.1M | $617.9M | $542.8M | $524.4M | $634.1M |
| Inventory | $2.3B | $2.2B | $2.4B | $2.1B | $2.1B | $2.5B | $2.4B | $2.3B | $2.1B | $2.0B |
| Total assets | $23.1B | $21.4B | $21.5B | $21.1B | $23.5B | $24.4B | $24.6B | $24.1B | $26.0B | $26.7B |
| Total liabilities | $10.4B | $8.9B | $9.0B | $9.0B | $10.8B | $12.2B | $12.2B | $12.9B | $14.3B | $17.0B |
| Shareholders' equity | $12.7B | $12.5B | $12.5B | $12.0B | $12.7B | $12.2B | $12.4B | $11.3B | $11.7B | $9.7B |
Growth · year-over-year · Revenue CAGR 0.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +7.2% | +3.8% | +6.5% | +1.6% | +11.4% | -23.2% | +0.6% | +1.7% | +1.8% | — |
| Net income growth | -22.0% | -11.7% | +342.5% | -42.4% | — | -112.3% | — | -120.9% | +492.9% | +108.1% |
| EPS growth | -19.9% | -9.2% | +343.6% | -42.4% | — | -112.2% | — | -120.9% | +489.4% | +96.1% |
| Free cash flow growth | +13.7% | +0.4% | +10.5% | -13.8% | +24.1% | -20.8% | -13.0% | +11.1% | -1.5% | +112.2% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.